Merck and Endocyte have published results from the Phase II trial for vintafolide, an investigational folate small molecule drug conjugate (SMDC). Those results form the basis for the vintafolide regulatory application currently under review with the EMA for the treatment of folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). Enrollment is ongoing in the treatment’s Phase III trial, which is being conducted along with invest...